Inspire drops out of accord on FAES Farma's bilastine

The USA's Inspire Pharmaceuticals has exercised its option to terminate the licensing agreement with Spanish drugmaker FAES Farma SA for the USA and Canadian development and commercialization of the latter's oral bilastine for the treatment of allergic rhinitis. Inspire says it is terminating the agreement in its entirety, and so is no longer responsible for the development and commercialization of the oral or ocular formulations of bilastine and has no further financial obligation to FAES, which is now seeking a new licensee. "We have made a strategic business decision to terminate the bilastine agreement and focus our resources and capital investments on our other late-stage development programs and commercial activities," said Inspire chief executive Christy Shaffer.